Skip to content
Bored Studies
RecruitingPhase 2/Phase 3

Phase 2/3 Efficacy and Safety of PP405 in Adult Males

Pelage Pharmaceuticals, Inc. · NCT07819435

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–55 · Men only
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2, Phase 3
Target enrollment
600
US sites recruiting
27
Study start
September 21, 2026
Record last updated
October 22, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The study is designed to validate efficacy and long term safety of PP405.

Being studied: PP405 0.05% Topical Gel; Vehicle Topical Gel

Conditions: Androgenetic Alopecia

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Males (assigned at birth) aged 18 to 55 years, inclusive at time of consent.
  • Able and willing to provide written informed consent
  • Must have been experiencing Androgenetic Alopecia (AGA) for at least 6 months prior to screening.
  • Have a modified Norwood-Hamilton score of Type IV or Type V
  • Agree to comply with protocol procedures

Exclusion Criteria

  • Concomitant diagnosis of non-AGA forms of alopecia.
  • Use of other hair loss treatments within periods specified in protocol.
  • Use of excluded medications and procedures as specified in protocol.
  • Diagnosis of other medical conditions as specified in protocol.
  • Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results.

Recruiting US locations

Study contacts (from the official record)

  • Lisa Sherman · 213-218-3830 · clinicaltrials@pelagepharma.com
All dermatology studies in Alabama →
Phase 2/3 Efficacy and Safety of PP405 in Adult Males (NCT07819435) | Bored Studies